First published 10/3/2026, 1:10:15 AM · Last updated 10/3/2026, 1:10:15 AM

P3.18.62 TRUST-III: Phase 3 Head-To-Head Study of Taletrectinib vs Crizotinib in Patients With ROS1+ Non-Small Cell Lung Cancer

An Elsevier journal article reports a Phase 3 head-to-head clinical study comparing taletrectinib and crizotinib for ROS1-positive non-small cell lung cancer patients. The supplied excerpt includes only publisher and content type and contains no study results, locations, or other details.

Illustrative image: Figure 1. ALK-rearrangement-targeted cancer therapy in non-small cell lung cancer. EML4-ALK translocation activates PI3K-AKT, RAS, and JAK/STAT signaling cascades, thereby influencing tumor progression, survival, and growth. ALK inhibitors such as crizotinib, alectinib, and brigatinib act on mutated ALKs, such as ELM4-ALK, and suppress the production of ALK fusion protein resulting from ALK rearrangement. EML4-ALK, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase; ALK, — Ando, K.; Akimoto, K.; Sato, H.; Manabe, R.; Kishino, Y.; Homma, T.; Kusumoto, S.; Yamaoka, T.; Tanaka, A.; Ohmori, T.;Hironori Sagara/Wikimedia Commons, CC BY 4.0

Categories: public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 3/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

This reports a Phase 3 clinical comparison between two therapies for ROS1-positive non-small cell lung cancer.

Sources

P3.18.62 TRUST-III: Phase 3 Head-To-Head Study of Taletrectinib vs Crizotinib in Patients With ROS1+ Non-Small Cell Lung Cancer

Report an issue